Mepartricin

This classification denotes a macrolide antibiotic with the molecular formula C60H88N2O19, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B7FBW3Y74G, chemically known as (4E,6E,8E,10Z,12Z,14E,16E)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-23,27,29,31,33,35,37-heptahydroxy-19-[5-hydroxy-7-[4-(methylamino)phenyl]-7-oxoheptan-2-yl]-18-methyl-21,25-dioxo-20,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carboxylate but generally known as Mepartricin, which bears US NIH Compound Identifier 6479653. European Medicines Agency schedules Mepartricin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03153MIG. The term MEPARTRICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 1). World Health Organization schedules azithromycin in its Anatomical Therapeutic Chemical (ATC) Classification. MEPARTRICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule mepartricin under HS 29419000 and SITC 54139. As of Q4 2014, MEPARTRICIN remains the US FDA Preferred Term for this commodity. SMILES: CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(CC(CC(CC(=O)CC(CC(=O)OC1C(C)CCC(CC(=O)C3=CC=C(C=C3)NC)O)O)O)O)O)O)O)O)C(=O)OC)OC4C(C(C(C(O4)C)O)N)O.